why choose us

First received: January 31, 2023

Clinical Trial: Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Study Status: Completed

Recruit Status: RECRUITING

Condition: Postbariatric Hypoglycemia

Study Type: INTERVENTIONAL


Official Title: Phase 2 Crossover, Randomized, Placebo-Controlled, Single-Blind, Repeat Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin on Adverse Events and Postprandial G

Brief Summary: This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.

Read more